These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32580098)

  • 21. The alpha-7 nicotinic acetylcholine receptor agonist GTS-21 engages the glucagon-like peptide-1 incretin hormone axis to lower levels of blood glucose in db/db mice.
    Meng Q; Chepurny OG; Leech CA; Pruekprasert N; Molnar ME; Collier JJ; Cooney RN; Holz GG
    Diabetes Obes Metab; 2022 Jul; 24(7):1255-1266. PubMed ID: 35293666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
    Pospisilik JA; Martin J; Doty T; Ehses JA; Pamir N; Lynn FC; Piteau S; Demuth HU; McIntosh CH; Pederson RA
    Diabetes; 2003 Mar; 52(3):741-50. PubMed ID: 12606516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The incretin system and its role in type 2 diabetes mellitus.
    Holst JJ; Vilsbøll T; Deacon CF
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice.
    Gumuslu E; Cine N; Ertan M; Mutlu O; Komsuoglu Celikyurt I; Ulak G
    Fundam Clin Pharmacol; 2018 Apr; 32(2):174-180. PubMed ID: 29091313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.
    Tura A; Bagger JI; Ferrannini E; Holst JJ; Knop FK; Vilsbøll T; Mari A
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1123-1129. PubMed ID: 29162361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice.
    Wei R; Cui X; Feng J; Gu L; Lang S; Wei T; Yang J; Liu J; Le Y; Wang H; Yang K; Hong T
    Metabolism; 2020 Oct; 111():154324. PubMed ID: 32712220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of acute NEFA manipulation on incretin-induced insulin secretion in participants with and without type 2 diabetes.
    Astiarraga B; Chueire VB; Souza AL; Pereira-Moreira R; Monte Alegre S; Natali A; Tura A; Mari A; Ferrannini E; Muscelli E
    Diabetologia; 2018 Aug; 61(8):1829-1837. PubMed ID: 29732475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antidiabetic drug therapy alleviates type 1 diabetes in mice by promoting pancreatic α-cell transdifferentiation.
    Sarnobat D; Moffett CR; Tanday N; Reimann F; Gribble FM; Flatt PR; Tarasov AI
    Biochem Pharmacol; 2020 Dec; 182():114216. PubMed ID: 32926875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
    Creutzfeldt W
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antihyperglycemic potential of incretins orally delivered via nano and microsystems and subsequent glucoregulatory effects.
    Araujo F; Shrestha N; Granja PL; Hirvonen J; Santos HA; Sarmento B
    Curr Pharm Biotechnol; 2014; 15(7):609-19. PubMed ID: 25219868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in micro- and nanotechnologies for the GLP-1-based therapy and imaging of pancreatic beta-cells.
    Moonschi FH; Hughes CB; Mussman GM; Fowlkes JL; Richards CI; Popescu I
    Acta Diabetol; 2018 May; 55(5):405-418. PubMed ID: 29264724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
    J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.
    Han J; Sun L; Huang X; Li Z; Zhang C; Qian H; Huang W
    Br J Pharmacol; 2014 Dec; 171(23):5252-64. PubMed ID: 25039358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose.
    Vardarli I; Arndt E; Deacon CF; Holst JJ; Nauck MA
    Diabetes; 2014 Feb; 63(2):663-74. PubMed ID: 24186866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of lipid nanocarriers for enhancing oral absorption and bioavailability of insulin and GLP-1 receptor agonists.
    Poudwal S; Misra A; Shende P
    J Drug Target; 2021 Sep; 29(8):834-847. PubMed ID: 33620269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential.
    Pathak NM; Pathak V; Gault VA; McClean S; Irwin N; Flatt PR
    Biochem Pharmacol; 2018 Sep; 155():264-274. PubMed ID: 30028989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oleanolic acid derivative DKS26 exerts antidiabetic and hepatoprotective effects in diabetic mice and promotes glucagon-like peptide-1 secretion and expression in intestinal cells.
    Chen FF; Wang JT; Zhang LX; Xing SF; Wang YX; Wang K; Deng SL; Zhang JQ; Tang L; Wu HS
    Br J Pharmacol; 2017 Sep; 174(17):2912-2928. PubMed ID: 28627773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
    Nauck MA
    Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Deacon CF
    Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():23-31. PubMed ID: 17877544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.